JPH01235591A - Production of catalase - Google Patents
Production of catalaseInfo
- Publication number
- JPH01235591A JPH01235591A JP5952788A JP5952788A JPH01235591A JP H01235591 A JPH01235591 A JP H01235591A JP 5952788 A JP5952788 A JP 5952788A JP 5952788 A JP5952788 A JP 5952788A JP H01235591 A JPH01235591 A JP H01235591A
- Authority
- JP
- Japan
- Prior art keywords
- catalase
- resin
- solution
- buffer
- chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000016938 Catalase Human genes 0.000 title claims abstract description 58
- 108010053835 Catalase Proteins 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 239000007864 aqueous solution Substances 0.000 claims abstract description 9
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 4
- 239000011347 resin Substances 0.000 abstract description 16
- 229920005989 resin Polymers 0.000 abstract description 16
- 239000000243 solution Substances 0.000 abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 229920002684 Sepharose Polymers 0.000 abstract description 5
- 239000007853 buffer solution Substances 0.000 abstract description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 5
- 229920002678 cellulose Polymers 0.000 abstract description 3
- 239000001913 cellulose Substances 0.000 abstract description 3
- 230000002209 hydrophobic effect Effects 0.000 abstract description 3
- 102000001554 Hemoglobins Human genes 0.000 abstract description 2
- 108010054147 Hemoglobins Proteins 0.000 abstract description 2
- 239000012153 distilled water Substances 0.000 abstract description 2
- 125000000524 functional group Chemical group 0.000 abstract description 2
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 239000012539 chromatography resin Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000872 buffer Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- -1 hydroxyl radicals Chemical compound 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GJMPSRSMBJLKKB-UHFFFAOYSA-N 3-methylphenylacetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1 GJMPSRSMBJLKKB-UHFFFAOYSA-N 0.000 description 1
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000591 Metallocarboxypeptidase D Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004192 high performance gel permeation chromatography Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940117957 triethanolamine hydrochloride Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、カタラーゼの製造方法に関し、さらに詳しく
は、カタラーゼ及び随伴する蛋白質を共に含む水溶液か
らカタラーゼを製造する方法に関する。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a method for producing catalase, and more particularly to a method for producing catalase from an aqueous solution containing both catalase and associated proteins.
(従来技術と発明が解決すべき課題)
カタラーゼは、生体内において、ヒドロキシルラジカル
などの活性酸素の生成に関与している過酸化水素を無害
な水と酸素に分解する酵素であ2H2022H20+O
2
したがって、カタラーゼは活性酸素によって引き起こさ
れる組織障害、例えば、炎症、変形性関節炎、慢性関節
リウマチ、未熟児酸素網膜症、白内障、アドリアマイシ
ンなどの制癌剤の副作用、虚血部分への血流再開に伴う
障害などに対する有効な治療剤として注目されている。(Prior art and problems to be solved by the invention) Catalase is an enzyme that decomposes hydrogen peroxide, which is involved in the generation of active oxygen such as hydroxyl radicals, into harmless water and oxygen in living organisms.
2 Therefore, catalase is involved in tissue damage caused by active oxygen, such as inflammation, osteoarthritis, rheumatoid arthritis, oxygen retinopathy of prematurity, cataracts, side effects of anticancer drugs such as adriamycin, and the resumption of blood flow to ischemic areas. It is attracting attention as an effective therapeutic agent for disorders.
従来、カタラーゼの精製法としては、カタラーゼ含有画
分を硫安分画、陰イオン交換クロマトグラフィー、陽イ
オン交換クロマトグラフィー、ゲル口過クロマトグラフ
ィーを組み合わせた方法[ジャーナル・オブ・バイオロ
ジカルφケミストリー、240.(11)、4299
(1965)]によって精製する方法が知られている。Conventionally, a method for purifying catalase is a method that combines a catalase-containing fraction with ammonium sulfate fractionation, anion exchange chromatography, cation exchange chromatography, and gel permeation chromatography [Journal of Biological φ Chemistry, 240]. .. (11), 4299
(1965)] is known.
ゲル口過クロマトグラフィーを用いる方法では、カタラ
ーゼの如く分子量の大きい蛋白質(分子量240.00
0)を工業的に大量処理することは、ゲル強度及び分離
能の面から困難である。また、イオン交換クロマトグラ
フィーを用いる方法では、カタラーゼそのものが持つ電
荷に関する不均一性により溶出が巾広く(ブロードに)
行われるため、溶出液量が増え、かつ、不純物との分離
が不十分であるなどの問題がある。In the method using gel filtration chromatography, proteins with large molecular weights such as catalase (molecular weight 240.00
It is difficult to industrially process large amounts of 0) in terms of gel strength and separation ability. In addition, in the method using ion exchange chromatography, the elution becomes broad due to the heterogeneity of the charge of catalase itself.
As a result, there are problems such as an increase in the amount of eluate and insufficient separation from impurities.
(課題を解決するための手段)
そこで、本発明者らは、カタラーゼを純度よく、かつ収
率よく得ることができ、さらに大量に処理することがで
きる方法を開発することを目的として鋭意研究を行った
結果、カタラーゼ及び随伴する蛋白質を共に含む水溶液
を疎水相互作用クロマトグラフィーにより処理すること
によって、カタラーゼを収率よく回収することができる
と伴に、不純物を効果的に除去することができ、さらに
、この方法は大量処理に適していることを見い出し、本
発明に到達した。(Means for Solving the Problems) Therefore, the present inventors have conducted extensive research with the aim of developing a method that can obtain catalase with high purity and high yield, and can also be processed in large quantities. As a result, by treating an aqueous solution containing both catalase and accompanying proteins by hydrophobic interaction chromatography, catalase can be recovered in good yield, and impurities can be effectively removed. Furthermore, we have discovered that this method is suitable for mass processing, and have arrived at the present invention.
本発明は、すなわち、カタラーゼ及び随伴する蛋白質を
共に含む水溶液からカタラーゼを疎水相互作用クロマト
グラフィーにより精製することを特徴とするカタラーゼ
の製造方法である。That is, the present invention is a method for producing catalase, which is characterized by purifying catalase from an aqueous solution containing both catalase and accompanying proteins by hydrophobic interaction chromatography.
本発明で使用されるカタラーゼ及び随伴する蛋白質を共
に含む水溶液は、赤血球、肝臓、胎盤等の動物由来組織
、植物組織、あるいは微生物から得ることができる0例
えば、赤血球に等量の蒸留水あるいは0.1〜0.5%
(W/V)の非イオン性界面活性剤を含む蒸留水を加え
て溶血した後、公知の方法によりヘモグロビンを除去す
ることによって得られるカタラーゼを含む両分が使用で
きる。好ましくは、さらにこの両分を硫安分画、陰イオ
ン交換クロマトグラフィー、陽イオン交換クロマトグラ
フィー、亜鉛を担持したメタルキレーティングアフィニ
ティクロマトグラフイーなどの公知の方法で精製するの
が好ましい、さらに好ましくは、これらの公知の方法を
組み合わせて、カタラーゼの含有率を高めた画分を使用
するのが好ましい、肝臓、胎盤などの動物由来組織ある
いは植物組織は、ホモジナイザーなどの装置を用いる公
知の方法により破砕して得られる水抽出液を上記方法で
精製してカタラーゼの含量を高めた両分を使用するのが
好ましい、微生物も公知の方法により破砕した後、上記
方法で精製してカタラーゼの含量を高めた両分を使用す
るのが好ましい、これらカタラーゼ含有画分の使用にお
いては、例えば、この両分中に、緩衝成分として10〜
50mMのリン酸塩あるいは10〜50mMのトリエタ
ノールアミン塩酸塩などのアミン塩酸塩を含有させ、イ
オン強度が1〜4、好ましくは2となるように塩化ナト
リウムなどの電解質を加えたのち、pHを6〜9、好ま
しくは6〜7に調整する。The aqueous solution containing both catalase and associated proteins used in the present invention can be obtained from animal-derived tissues such as red blood cells, liver, and placenta, plant tissues, or microorganisms. .1~0.5%
After hemolyzing by adding (W/V) distilled water containing a nonionic surfactant, both fractions containing catalase can be used by removing hemoglobin by a known method. Preferably, both components are further purified by a known method such as ammonium sulfate fractionation, anion exchange chromatography, cation exchange chromatography, zinc-supported metal chelating affinity chromatography, and more preferably. It is preferable to use a fraction with an increased content of catalase by combining these known methods. Animal-derived tissues such as liver and placenta or plant tissues are disrupted by a known method using a device such as a homogenizer. It is preferable to use the aqueous extract obtained by purifying the obtained water extract by the above method to increase the catalase content. In the use of these catalase-containing fractions, for example, it is preferable to use both fractions as a buffer component.
Contain 50mM phosphate or 10-50mM amine hydrochloride such as triethanolamine hydrochloride, add an electrolyte such as sodium chloride so that the ionic strength is 1-4, preferably 2, and then adjust the pH. Adjust to 6-9, preferably 6-7.
本発明で使用される疎水相互作用クロマトグラフィーの
樹脂の例としては、セルロース、アガロース、合成ホリ
マーなどの担体に、フェニル基、オクチル基、ブチル基
などの疎水性の官能基を担持した樹脂が挙げられる。具
体的な例として、オクチル・セファロースCL−4B
(ファルマシア社)、フェニル争セファロースCL−4
B(ファルマシア社)、ブチル・セファロース4B(フ
ァルマシア社)およびブチルトヨパール650(東ソー
株)などが挙げられる。Examples of resins for hydrophobic interaction chromatography used in the present invention include resins in which hydrophobic functional groups such as phenyl, octyl, and butyl groups are supported on carriers such as cellulose, agarose, and synthetic polymers. It will be done. As a specific example, Octyl Sepharose CL-4B
(Pharmacia), Phenyl Sepharose CL-4
B (Pharmacia), Butyl Sepharose 4B (Pharmacia), and Butyl Toyopearl 650 (Tosoh).
本発明の方法は、通常、前記の方法で得、イオン強度お
よびpHを調整したカタラーゼ含有液を、カタラーゼ含
有液の調整に用いたkl#成分及び電解質を用いて同じ
組成のPHの緩衝液(緩衝液A)を樹脂量の5〜10倍
量用いて平衡化した樹脂に通すことによって行われる。In the method of the present invention, the catalase-containing solution obtained by the above method and adjusted in ionic strength and pH is usually mixed with a buffer solution (with the same composition and pH) using the kl# component and electrolyte used for preparing the catalase-containing solution. This is done by passing buffer A) through a resin equilibrated with 5 to 10 times the amount of resin.
樹脂に通すカタラーゼ及び随伴する蛋白質の量は、樹脂
100−に対して、カタラーゼ及び随伴する蛋白質を共
に含む □水溶液中の総蛋白質が500mg以下
、そのうちカタラーゼは250mg以下であることが望
ましい、目的とするカタラーゼは、樹脂を樹脂量の3〜
lO倍、好ましくは5倍量の緩衝液Aで洗浄し、次いで
カタラーゼ含有液の調整に用いた電解質のイオン強度が
0.5〜lの該電解質を含む緩衝液を樹脂の5〜lO倍
量用いて展開して、不純物を除いたのち、緩衝成分のみ
からなる緩衝液、pH6〜9、好ましくはpH7で展開
することにょって得ることができる0本発明の方法によ
って得られるカタラーゼ標品は、これまでの既知の方法
で得られる物よりも非常に高純度であることが、以下の
分析で確認された。すなわち、ポリアクリルアミド電気
泳動法において、単一バンドであり、ドデシル硫酸ナト
リウム存在下のポリアクリルアミド電気泳動法では、分
子量59.000の単一バンドを与えた。また、高速液
体クロマトグラフィーによるゲル口過分析は、市販品(
シグマ社)の主ピークと同じ位置に単一のピークを示し
、分子量は190.000と推定することができた。鉄
の含量は、イオンカップルドプラズマ分光法による分析
の結果、カタラーゼ1分子中に4g原子であることが確
認された。The amount of catalase and accompanying protein to be passed through the resin includes both catalase and accompanying protein per 100 mm of resin. □ It is desirable that the total protein in the aqueous solution is 500 mg or less, of which catalase is 250 mg or less. The catalase that is
Wash with 1O times, preferably 5 times the amount of buffer A, and then add 5 to 1O times the amount of the buffer containing the electrolyte used to prepare the catalase-containing solution, the ionic strength of which is 0.5 to 1. The catalase preparation obtained by the method of the present invention can be obtained by developing with a buffer solution containing only buffer components, pH 6 to 9, preferably pH 7, after removing impurities. The following analysis confirmed that the purity was much higher than that obtained by previously known methods. That is, a single band was obtained in polyacrylamide electrophoresis, and a single band with a molecular weight of 59,000 was obtained in polyacrylamide electrophoresis in the presence of sodium dodecyl sulfate. In addition, gel filtration analysis using high-performance liquid chromatography can be performed using commercially available products (
A single peak was observed at the same position as the main peak of Sigma), and the molecular weight could be estimated to be 190,000. As a result of analysis using ion-coupled plasma spectroscopy, it was confirmed that the iron content was 4g atoms in one molecule of catalase.
(実施例)
本発明を実施例及び参考例により更に説明するが、これ
らの例により本発明が限定を受けるものではない。(Examples) The present invention will be further explained by Examples and Reference Examples, but the present invention is not limited by these Examples.
参考例1
3週間、4°Cにて保存したヒ)CPD加濃厚赤血球を
4℃、1500xcで15分間遠心分離した。上清液を
除去後、沈降した赤血球を生理食塩水で3回洗浄し、こ
の赤血球沈殿l容に、0.2%(W/V)のサポニンを
含む冷水l容を加え、4℃で1時間撹拌し溶血した。溶
血液を透析用セルロースチューブに入れ、4℃で、1m
Mリン酸緩衝液(pH7、2)に対して透析脱塩を行っ
た。透析後の溶血液に0.1%(W/V)濃度になるよ
うに、トリトンX−100を添加じ、pHを7.2に調
整した。1mMリン酸緩衝液(pH7,2)で平衡化し
たDE−52(ワットマン社)を用い、上記の処理を施
した溶血液をバッチワイズにより処理し、蛋白質の吸着
したDE−52を平衡化に用いた同一の緩衝液で洗浄し
、非吸着物を洗い流した。洗浄後の蛋白の吸着したDE
−52をカラムにつめ、DE−52の樹脂容量の3倍量
の50mMリン酸緩衝液(pH6、8)で展開し、カタ
ラーゼを含む画分を得た。Reference Example 1 Human CPD enriched red blood cells stored at 4°C for 3 weeks were centrifuged at 1500xc for 15 minutes at 4°C. After removing the supernatant, the precipitated red blood cells were washed three times with physiological saline, and one volume of cold water containing 0.2% (W/V) saponin was added to one volume of this red blood cell sediment, and the mixture was incubated at 4°C for 1 hour. The mixture was stirred for hours to cause hemolysis. Put the lysed hemolysate into a cellulose tube for dialysis, and place it in a 1 m tube at 4°C.
Dialysis desalting was performed against M phosphate buffer (pH 7, 2). Triton X-100 was added to the hemolysate after dialysis to a concentration of 0.1% (W/V), and the pH was adjusted to 7.2. Using DE-52 (Whatman) equilibrated with 1mM phosphate buffer (pH 7,2), the hemolysate subjected to the above treatment was treated batchwise, and the protein-adsorbed DE-52 was equilibrated. Washing was performed with the same buffer used to wash away non-adsorbed substances. DE with protein adsorbed after washing
-52 was packed into a column and developed with 50 mM phosphate buffer (pH 6, 8) in an amount three times the resin volume of DE-52 to obtain a fraction containing catalase.
参考例2
参考例1において得られたカタラーゼを含む両分に、そ
の容量100m1に対して70gの硫酸アンモニウム(
生化学用)を加え、溶解させ、4℃で一晩放置した。生
じた沈殿を4℃、7700XG、30分間の遠心分離に
より回収した。沈殿に10mM)リエタノールアミン塩
酸塩からなる緩衝液(p)17 、0)を加え、沈殿を
溶解し、これと同一の緩衝液に対して透析し、脱塩を行
った。DEAE−セファロース・ファーストフロラ(フ
ァルマシア社)をカラムにつめ、上記と同一の緩衝液で
平衡化し、脱塩後のカタラーゼを含む両分を通し、平衡
化に用いた緩衝液で洗浄した。樹脂容量の5倍量の、5
0mM塩化ナトリウムを含む上記緩衝液で展開し、カタ
ラーゼを含む画分を得た。Reference Example 2 70g of ammonium sulfate (
(for biochemistry) was added, dissolved, and left overnight at 4°C. The resulting precipitate was collected by centrifugation at 4°C, 7700XG, for 30 minutes. A buffer (p)17,0) consisting of 10mM) reethanolamine hydrochloride was added to the precipitate to dissolve the precipitate, and the precipitate was dialyzed against the same buffer for desalting. DEAE-Sepharose Fastflora (Pharmacia) was packed in a column, equilibrated with the same buffer as above, and both columns containing catalase after desalting were passed through and washed with the buffer used for equilibration. 5 times the resin capacity
It was developed with the above buffer containing 0 mM sodium chloride to obtain a fraction containing catalase.
参考例3
参考例2において得られたカタラーゼを含む画分に0.
5M1M度になるように塩化ナトリウムを加えた。キレ
−ティングセファロース6B(ファルマシア社)樹脂1
00−に対して、2 、85solの硫酸亜鉛を吸着さ
せ、水洗し、0.5M塩化ナトリウムを含む10mM)
リエタノールアミン塩酸塩からなる緩衝液(pH7、0
)で平衡化した。これに上記のカタラーゼを含む両分を
通し、平衡化に用いた同一の緩衝液で洗浄した。吸着画
分の展開は、平衡化に用いた同一の緩衝液に5mM濃度
になるように酢酸を添加することにより実施した。この
画分のカタラーゼの高速ゲル口過クロマトグラフィー(
装置としてFPLCシステム、カラムとしてスーパーロ
ーズ・ティー・エム12、ファルマシア社)による分析
の結果、この両分のカタラーゼの含量は約70%であっ
た。Reference Example 3 0.0% was added to the catalase-containing fraction obtained in Reference Example 2.
Sodium chloride was added to make 5M to 1M degrees. Chelating Sepharose 6B (Pharmacia) Resin 1
00-, adsorbed 2.85 sol of zinc sulfate, washed with water, and prepared 10 mM containing 0.5 M sodium chloride).
Buffer solution consisting of reethanolamine hydrochloride (pH 7, 0
). Both portions containing the above catalase were passed through this and washed with the same buffer used for equilibration. Development of the adsorbed fraction was carried out by adding acetic acid to the same buffer used for equilibration to a concentration of 5 mM. High performance gel permeation chromatography of catalase in this fraction (
As a result of analysis using an FPLC system as an apparatus and a Superrose TM 12 column (Pharmacia), the content of catalase in both components was approximately 70%.
実施例1
フェニルセファロースCL−4B (ファルマシア社製
)樹脂200t7をカラムにつめ、2L;Lの2M塩化
ナトリウムを含む10mM)リエタノールアミン塩酸塩
M衝液(pH7)を通し、平衡化した0次に参考例3で
得た粗製カタラーゼ両分1.5文に2M濃度になるよう
に塩化ナトリウムを加えて溶かした。この溶液を上記の
フェニルセファロースCL−4Bに通し、カタラーゼを
吸着させた。141の平衡化緩衝液、次いで0.05M
リン酸緩衝液+LM塩化ナトリウム(pH7,0)1文
、さらに0.05Mリン酸緩衝液+0.5M塩化ナトリ
ウム(pH7、0) 11で洗浄した。カタラーゼの展
開は、0.05Mリン酸緩衝液(pH7.0)を1文通
すことによって行った。得られたカタラーゼ画分の高速
ゲル口過クロマトグラフィー(装置としてFPLCシス
テム、カラムとしてスーパーローズ・ティー・エム12
、ファルマシア社)による分析の結果、この両分のカタ
ラーゼの含量は98%以上であり、ポリアクリルアミド
電気泳動法によっても単一のバンドを示した。参考例3
において得られたカタラーゼ画分からカタラーゼの活性
回収率は52%であった。参考例及び実施例にしたがい
精製することにより、赤血球2.5又より550mgの
カタラーゼを得ることができた。なお、カタラーゼの活
性測定はシンハの方法に従って行った[アナリティカル
・バイオケミストリー、生7,389 (1972)参
照]。Example 1 Phenyl Sepharose CL-4B (manufactured by Pharmacia) resin 200t7 was packed in a column, and passed through 2 L of 10 mM) reethanolamine hydrochloride M solution (pH 7) containing 2 M sodium chloride to equilibrate the zero order. Sodium chloride was added to 1.5 grams of the crude catalase obtained in Reference Example 3 to give a concentration of 2M and dissolved. This solution was passed through the above-mentioned Phenyl Sepharose CL-4B to adsorb catalase. 141 equilibration buffer, then 0.05M
It was washed with 1 part of phosphate buffer + LM sodium chloride (pH 7,0) and then 1 part of 0.05 M phosphate buffer + 0.5 M sodium chloride (pH 7, 0). Development of catalase was performed by passing one portion of 0.05M phosphate buffer (pH 7.0) through. High-speed gel permeation chromatography of the obtained catalase fraction (FPLC system as device, Superrose TM 12 as column)
As a result of an analysis by a company (Pharmacia, Inc.), the content of catalase in both components was 98% or more, and polyacrylamide electrophoresis also showed a single band. Reference example 3
The recovery rate of catalase activity from the catalase fraction obtained was 52%. By purifying according to the Reference Examples and Examples, 550 mg of catalase could be obtained from 2.5 red blood cells. The activity of catalase was measured according to the method of Sinha [see Analytical Biochemistry, Sei 7, 389 (1972)].
(発明の効果)
以上詳述したところから明らかなように、本発明方法に
よれば、カタラーゼ及び随伴蛋白を含有する水溶液から
効率よく不純物を除去して、カタラーゼを収率よ〈回収
することができ、かつ大量処理が回旋であるため高純度
カタラーゼを大量に供給することができる。(Effects of the Invention) As is clear from the above detailed description, according to the method of the present invention, impurities can be efficiently removed from an aqueous solution containing catalase and associated proteins, and catalase can be recovered with a higher yield. Moreover, since large-scale processing is done by rotation, high-purity catalase can be supplied in large quantities.
Claims (1)
タラーゼを疎水相互作用クロマトグラフィーにより精製
することを特徴とするカタラーゼの製造方法A method for producing catalase, which comprises purifying catalase from an aqueous solution containing both catalase and accompanying proteins by hydrophobic interaction chromatography.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5952788A JPH01235591A (en) | 1988-03-15 | 1988-03-15 | Production of catalase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5952788A JPH01235591A (en) | 1988-03-15 | 1988-03-15 | Production of catalase |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01235591A true JPH01235591A (en) | 1989-09-20 |
Family
ID=13115837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5952788A Pending JPH01235591A (en) | 1988-03-15 | 1988-03-15 | Production of catalase |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01235591A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60217893A (en) * | 1984-04-12 | 1985-10-31 | Morinaga & Co Ltd | Preparation of arginyl transferase |
-
1988
- 1988-03-15 JP JP5952788A patent/JPH01235591A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60217893A (en) * | 1984-04-12 | 1985-10-31 | Morinaga & Co Ltd | Preparation of arginyl transferase |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0171086B1 (en) | A method for purification of influenza virus | |
Aronsson et al. | Characterization of glyoxalase I purified from pig erythrocytes by affinity chromatography | |
US5679776A (en) | Process for preparing a concentrate of blood coagulation factor VIII-von willebrand factor complex from total plasma | |
US4075193A (en) | Process for producing intravenous immune globulin | |
JPS63255300A (en) | Method for separating and purifying lactoferrin from milk using sulfuric acid esterification product | |
JP3438735B2 (en) | Method for isolating human albumin from supernatant IV, especially IV-4 or corn fraction V or a similar supernatant or fraction | |
JPS59137417A (en) | Preparation of colonization stimulation factor and kallikrein originated from human urine | |
Davis et al. | Purification, molecular properties, and amino acid composition of the subunits of Rhodospirillum rubrum succinate dehydrogenase | |
JPS58201794A (en) | Purification of human interferon through concentration | |
US4380511A (en) | Purification of bovine thrombin | |
JPH0133158B2 (en) | ||
JPH06321994A (en) | Antithrombin preparation and method of its preparation | |
JPH04295432A (en) | Complex containing blood coagulation factor ix | |
US4510084A (en) | Method of producing an antithrombin III-heparin concentrate or antithrombin III-heparinoid concentrate | |
JPH0386900A (en) | Novel thrombin-combining substance and production its | |
JPH05279396A (en) | Method for purification of factor viii and preparation obtained by the method | |
JPH02113893A (en) | Method for concentrating one or more of coagulation factors ii, vii, ix, x | |
JPH01235591A (en) | Production of catalase | |
Paschke et al. | Multiple forms of 2-deoxy-D-glucoside-2-sulphamate sulphohydrolase from human placenta | |
KR20020057960A (en) | Method of purifying calcium ion-binding protein | |
JPH01235590A (en) | Production of erythrocyte derived cu, zn type superoxide dismutase and catalase | |
JP2722140B2 (en) | Method for producing human urinary trypsin inhibitor | |
JPS589686A (en) | Purifying method of superoxide dismutase | |
JPS6031479B2 (en) | Method for producing pure chondroitinase C | |
JPH01235588A (en) | Production of erythrocyte derived cu, zn type superoxide dismutase and catalase |